Stock Markets May 5, 2026 08:59 AM

IQVIA Shares Slip After Q1 Book-to-Bill Misses Expectations

Contract research provider posts earnings and revenue beats but a softer-than-expected book-to-bill ratio weighs on premarket trading

By Marcus Reed IQV
IQVIA Shares Slip After Q1 Book-to-Bill Misses Expectations
IQV

IQVIA Holdings stock fell in premarket trading after the contract research firm reported a first-quarter book-to-bill ratio of 1.04x that missed analyst expectations. The quarter included an adjusted EPS beat and revenue above consensus, and the company raised its full-year 2026 earnings outlook, but investors focused on the book-to-bill reading.

Key Points

  • IQVIA's first-quarter book-to-bill ratio came in at 1.04x, below the average analyst estimate.
  • Adjusted EPS of $2.90 and revenue of $4.15 billion both beat consensus estimates.
  • Company raised full-year 2026 adjusted earnings guidance to $12.65-$12.95 per share; analysts had expected $12.70.

IQVIA Holdings (NYSE:IQV) shares declined 3.7% to $154.99 in premarket trading Tuesday after the contract research firm disclosed a first-quarter book-to-bill ratio that fell short of analyst expectations.

The company reported a first-quarter book-to-bill ratio of 1.04x, a measure comparing the value of new orders to billings, which missed the average estimate from analysts, according to Reuters.

Despite the book-to-bill shortfall, IQVIA posted adjusted earnings of $2.90 per share for the quarter, topping the average analyst estimate of $2.82 per share. Revenue for the period reached $4.15 billion, also ahead of the $4.10 billion consensus.

Leerink Partners analyst Michael Cherny commented on the results, saying "the headline that will likely be the main focus is the 1.04x book-to-bill" and that this metric would "overshadow what was an otherwise solid print across the board."

Management updated its full-year outlook for 2026, raising adjusted earnings guidance to a range of $12.65 to $12.95 per share from the prior range of $12.55 to $12.85 per share. Analysts had been expecting 2026 earnings of $12.70 per share.

Investors had already pushed IQVIA shares lower this year: as of Monday's close the stock had declined 28.6% year-to-date.


Context and market reaction

Market attention centered on the book-to-bill figure, which the analyst community flagged as the most notable datapoint from the release. While earnings and revenue beat consensus, the softer book-to-bill reading prompted the premarket decline in the share price.


Key takeaways

  • Book-to-bill ratio: IQVIA reported a first-quarter book-to-bill of 1.04x, below the average analyst expectation.
  • Earnings and revenue: Adjusted EPS of $2.90 and revenue of $4.15 billion both exceeded consensus estimates, indicating operational strength in the quarter.
  • Guidance and market position: The company raised its 2026 adjusted earnings outlook to $12.65-$12.95 per share; analysts had expected $12.70. Sectors impacted include healthcare services, contract research, and equity markets.

Risks and uncertainties

  • Investor focus on book-to-bill: Market reaction may remain sensitive to bookings metrics, which could continue to influence share price despite solid reported earnings and revenue.
  • Guidance interpretation: Although IQVIA raised its 2026 earnings range, analysts' expectation of $12.70 per share sits within that range, leaving room for differing interpretations by investors.
  • Share performance: The stock's 28.6% year-to-date decline through Monday's close highlights existing market concerns that could persist until booking trends clarify.

Note: This article presents the company's reported figures and analyst comments as released. It does not introduce new forecasts or speculate beyond the information provided by the company and quoted analyst remarks.

Risks

  • Market attention on the below-expectation 1.04x book-to-bill ratio could pressure the stock despite earnings and revenue beats - impacts equity markets and healthcare services.
  • The raised 2026 guidance range leaves room for varied investor interpretation given the $12.70 analyst expectation - affects investor sentiment in contract research and pharmaceuticals exposure.
  • The stock's 28.6% year-to-date decline through Monday's close underscores ongoing investor concerns that may persist until booking trends improve - relevant to financial markets and healthcare-sector investors.

More from Stock Markets

SAP to Extend AI Capabilities to On-Premise Customers, Plans Announcement at Sapphire May 5, 2026 Suzano Poised to Secure Full EU Approval for $3.4 Billion Kimberly-Clark Tissue JV May 5, 2026 Major publishers sue Meta over alleged use of books and articles to train Llama AI May 5, 2026 SEC Moves to Rescind Biden-Era Climate Disclosure Rule May 5, 2026 GameStop’s $56 Billion Offer for eBay Sparks Social Media Frenzy and Fresh Doubts May 5, 2026